Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. (). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Stereotactic Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ). J Thorac Oncol. SLOTMAN B, SENAN S. Radiother. Slotman BJ, Senan S. SLOTMAN BJ, VOS PH. Salzman & Colburn () evidenciaram que Slotman, K. . Kumar,. Oncol. , & Reijneveld, S. Experiences of case managers in providing. ; (2), KIM MS et al. Radiobiological. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Planning of radiotherapy capacity and productivity. Slotman BJ, van Tinteren H, Praag JO, et al.